Proportion of nursing home admissions: results of OLS regression analyses.
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
Intercept -138.70 21.85* 72.14 -26.70 27.45* -241.43 -195.13*
[-413.96; 136.55] [ 6.44; 37.25] [-1.43; 145.70] [-171.88; 118.47] [21.95; 32.96] [-586.44; 103.58] [-321.66; -68.59]
Composition: General practitioners 1.64 1.66 1.01*
[ -1.11; 4.40] [ -1.33; 4.65] [ 0.01; 2.00]
Composition: Ophtalmologists 2.86 0.44
[ -0.53; 6.25] [ -2.99; 3.88]
Composition: Surgeons 1.35 1.74 0.94
[ -1.63; 4.33] [ -1.42; 4.90] [ -0.38; 2.26]
Composition: Multidisciplinary practices 1.57 1.99 1.34*
[ -1.19; 4.32] [ -0.97; 4.95] [ 0.40; 2.27]
Composition: Therapists 1.65 1.80 1.20*
[ -1.10; 4.40] [ -1.17; 4.76] [ 0.29; 2.11]
Composition: Internists 2.28 2.29 1.56*
[ -0.59; 5.15] [ -0.81; 5.38] [ 0.45; 2.67]
Composition: Orthopedics 0.12 2.15 1.48
[ -3.09; 3.32] [ -1.08; 5.38] [ -0.19; 3.15]
Composition: Psychologists and psychotherapists 1.16 2.07 1.39*
[ -1.57; 3.89] [ -0.89; 5.03] [ 0.37; 2.41]
Composition: Other disciplines 1.69 1.83 1.21*
[ -1.08; 4.46] [ -1.16; 4.81] [ 0.25; 2.17]
Composition: Urologists 0.77 0.24
[ -2.77; 4.32] [ -3.37; 3.85]
Composition: Rehabilitation facilities 0.04 2.46 1.61*
[ -2.75; 2.83] [ -0.51; 5.43] [ 0.06; 3.15]
Composition: Hospitals -0.79 1.71
[ -3.58; 2.01] [ -1.50; 4.92]
Composition: Proportion of care-dependent persons in cluster -0.42* -1.01* -0.98*
[ -0.70; -0.13] [ -1.45; -0.57] [ -1.33; -0.64]
Composition: Logarithm of number of providers in cluster 1.22* -0.90
[ 0.21; 2.24] [ -2.15; 0.36]
No. of Comorbidities 11.03 19.80 13.26
[-15.96; 38.01] [ -14.15; 53.76] [ -0.30; 26.81]
COC Asthma 0.25 0.50
[ -1.81; 2.31] [ -1.74; 2.75]
SECON Asthma 0.02 0.18
[ -1.32; 1.35] [ -1.26; 1.61]
UPC Asthma -0.79 -1.66 -0.67
[ -3.87; 2.29] [ -5.03; 1.72] [ -1.36; 0.03]
COC COPD -7.69* -1.77 -2.40*
[ -11.83; -3.54] [ -6.91; 3.37] [ -4.54; -0.27]
SECON COPD -1.14 -1.91 -1.50*
[ -3.05; 0.77] [ -4.08; 0.27] [ -2.79; -0.20]
UPC COPD 10.92* 4.41 4.78*
[ 5.63; 16.22] [ -1.94; 10.75] [ 2.13; 7.43]
COC Dementia 2.13 -0.82 -1.09
[ -2.37; 6.62] [ -5.40; 3.76] [ -2.28; 0.09]
SECON Dementia 1.40 2.75* 2.38*
[ -0.57; 3.37] [ 0.65; 4.85] [ 0.61; 4.15]
UPC Dementia -4.00 -0.53
[ -9.72; 1.72] [ -6.39; 5.32]
COC Diabetes 4.12* -0.21
[ 0.18; 8.07] [ -5.11; 4.68]
SECON Diabetes 1.03 1.00 1.09
[ -0.68; 2.74] [ -1.08; 3.07] [ -0.19; 2.38]
UPC Diabetes -5.98* -1.07 -1.36
[ -10.48; -1.48] [ -6.49; 4.35] [ -2.73; 0.01]
COC Heart Failure -0.31 0.17
[ -2.51; 1.89] [ -2.19; 2.53]
SECON Heart Failure -0.26 -0.63
[ -1.33; 0.81] [ -1.96; 0.70]
UPC Heart Failure 0.63 0.68 0.38
[ -2.19; 3.44] [ -2.25; 3.61] [ -0.06; 0.82]
Asthma: Prevalence 0.56 -0.81 -0.77
[ -0.32; 1.45] [ -1.99; 0.38] [ -1.72; 0.17]
Asthma: Spirometry 0.03 -0.09 -0.13
[-0.09; 0.15] [ -0.28; 0.09] [ -0.29; 0.04]
Asthma: Inhalative medication 0.04 0.13
[-0.14; 0.23] [ -0.09; 0.34]
Asthma: ICS 0.14 0.13 0.16*
[-0.02; 0.30] [ -0.05; 0.31] [ 0.03; 0.29]
Medication: PRISCUS -0.87* -1.14* -1.26*
[-1.49; -0.25] [ -1.92; -0.36] [ -1.82; -0.71]
Medication: Beta-Blocker after myocardial infarction 0.07 0.07
[-0.36; 0.50] [ -0.40; 0.54]
Medication: ACE-inhibitor upon hypertension and renal insufficiency a -0.13 -0.19
[-0.60; 0.33] [ -0.65; 0.27]
Medication: ACE-inhibitor upon heart failure -0.06 -0.44 -0.56*
[-0.60; 0.47] [ -1.00; 0.13] [ -0.91; -0.21]
Medication: Beta-blocker upon asthma -0.32 -0.28
[-0.73; 0.10] [ -0.72; 0.15]
Medication: Eletrolyte check upon diuretics 0.04 -0.07
[-0.21; 0.29] [ -0.34; 0.20]
Medication: Polypharmacy 0.76* 0.93* 0.72*
[ 0.24; 1.29] [ 0.21; 1.65] [ 0.22; 1.23]
Ambulatory care sensitive cases -0.09 -0.02
[-1.81; 1.63] [ -2.91; 2.87]
COPD: Prevalence -1.07* -0.21
[ -1.65; -0.50] [ -0.96; 0.53]
COPD: Inhalative medication 0.10 -0.07
[-0.28; 0.47] [ -0.50; 0.36]
COPD: Acute inpatient treatment -2.28* 2.81* 2.17*
[-4.33; -0.23] [ 0.06; 5.57] [ 0.32; 4.02]
COPD: Respiratory therapy -0.14 0.06
[-0.60; 0.33] [ -0.53; 0.66]
COPD: influenca vaccination 1.01 0.38
[-0.55; 2.56] [ -1.17; 1.92]
COPD: Specific beta-blocker therapy -0.22 -0.13
[-0.61; 0.18] [ -0.57; 0.31]
COPD: Specific anticholinergic therapy 0.03 0.01
[-0.31; 0.37] [ -0.35; 0.37]
COPD: Oral corticosteroids -0.23 -0.21
[-0.73; 0.27] [ -0.76; 0.33]
CVD: Prevalence hypertension -0.20 -0.44 -0.41
[ -0.63; 0.23] [ -1.02; 0.13] [ -0.84; 0.01]
CVD: Medication for hypertension 0.24 0.01
[-0.48; 0.96] [ -0.80; 0.82]
CVD: Prevalence heart failure -1.47* -2.12* -1.92*
[ -2.48; -0.47] [ -3.49; -0.75] [ -3.01; -0.82]
CVD: Echocardiography upon heart failure -0.24* -0.15* -0.12
[-0.38; -0.10] [ -0.29; -0.01] [ -0.25; 0.00]
CVD: 12-lead ECG upon heart failure -0.06 -0.05 -0.10
[-0.19; 0.07] [ -0.18; 0.08] [ -0.21; 0.02]
CVD: ACE-inhibiter upon heart failure -0.08 0.48 0.80*
[-0.56; 0.41] [ -0.05; 1.02] [ 0.38; 1.23]
CVD: Beta-blocker upon heart failure 0.23 0.26
[-0.13; 0.58] [ -0.11; 0.63]
CVD: Anticoagulant upon artrial fibrillation and heart failure -0.29 -0.30 -0.24
[-0.68; 0.09] [ -0.70; 0.10] [ -0.56; 0.09]
CVD: Referral to cardiologist upon heart failure -0.05 -0.00
[-0.14; 0.04] [ -0.10; 0.09]
CVD: Acute inpatient treatment of heart failure 0.18 -0.37 -0.33*
[-0.10; 0.46] [ -0.76; 0.01] [ -0.65; -0.02]
CVD: Apoplexy treatment in stroke unit 0.47 0.68 0.69
[-0.30; 1.25] [ -0.12; 1.48] [ -0.01; 1.39]
CVD: Platelet aggregation inhibitor upon stable chronic coronary heart disease -0.10 -0.01
[-0.44; 0.25] [ -0.38; 0.35]
CVD: Statins upon coronary heart disease -0.18 -0.57* -0.47*
[-0.49; 0.14] [ -0.92; -0.21] [ -0.72; -0.22]
CVD: Anti-hypertensive therapy upon coronary heart disease and hypertension 0.00 0.64
[-1.01; 1.02] [ -0.45; 1.72]
Dementia: Prevalence 1.46* 2.02* 1.79*
[ 0.23; 2.70] [ 0.61; 3.44] [ 0.68; 2.90]
Dementia: B12 and TSH 0.67 0.50
[-0.07; 1.41] [ -0.31; 1.31]
T2D: Prevalence 0.29 -0.15
[ -0.18; 0.77] [ -0.79; 0.49]
T2D: HbA1c -0.15* -0.19* -0.23*
[-0.29; -0.00] [ -0.37; -0.01] [ -0.37; -0.10]
T2D: Ophtalmological examination 0.03 0.14
[-0.20; 0.26] [ -0.11; 0.39]
T2D: Fundus examination -0.23 -0.09
[-0.52; 0.05] [ -0.40; 0.22]
T2D: Triglycerides and cholesterol -0.19* -0.13 -0.18*
[-0.32; -0.07] [ -0.26; 0.01] [ -0.29; -0.06]
T2D: Hypertension, nepropathy and A -0.14 -0.42* -0.53*
[-0.44; 0.17] [ -0.74; -0.11] [ -0.79; -0.27]
T2D: Serum-creatinin -0.03 0.11 0.10
[-0.20; 0.14] [ -0.09; 0.30] [ -0.04; 0.25]
Osteoarthritis: Prevalence 0.01 -0.03
[ -0.41; 0.42] [ -0.57; 0.50]
Osteoporosis: Prevalence -0.17 -0.45 -0.49
[ -0.72; 0.38] [ -1.07; 0.18] [ -0.99; 0.00]
Prevention: Influenca vaccination -0.99 -0.74
[-2.74; 0.77] [ -2.61; 1.13]
Prevention: Mammography -0.36 -0.25
[-0.83; 0.11] [ -0.81; 0.31]
Prevention: Faecal occult blood test 0.22 0.07
[-2.07; 2.51] [ -2.32; 2.46]
Prevention: Men's cancer screening -0.34 -0.43 -0.59*
[-1.03; 0.35] [ -1.13; 0.27] [ -1.17; -0.00]
Prevention: Skin-cancer screening 1.19 -1.06
[-2.28; 4.65] [ -4.70; 2.58]
Depression: Prevalence -0.54* -0.41
[ -0.99; -0.09] [ -1.09; 0.27]
Depression: Anti-depressive pharmacotherapy -0.18 -0.25
[-0.44; 0.08] [ -0.55; 0.04]
No. of variables 14 10 40 15 3 82 34
Num. obs. 407 407 407 407 407 407 407
R2 0.11 0.20 0.33 0.21 0.02 0.49 0.46
Adj. R2 0.08 0.18 0.26 0.18 0.01 0.36 0.40
AIC 3058 3010 2996 3013 3078 2967 2912
* 0 outside the confidence interval.